Skip to main content
Premium Trial:

Request an Annual Quote

Sirna Licenses Tuschl s RNAi Technology from UMass

This article has been updated from a previous version to include comments from a Sirna Therapeutics spokeswoman and additional information on other licensees of the intellectual property.

NEW YORK, Sept. 9 (GenomeWeb News) - Sirna Therapeutics of Boulder, Colo., has entered into a worldwide license agreement with the University of Massachusetts Medical School for RNA interference technology covering short interfering RNA, the company said today.

The license covers a patent application filed by RNAi pioneer Thomas Tuschl and colleagues (International PCT Publication No. WO 01/75164), which was jointly developed and is owned by the University of Massachusetts Medical School, Max-Planck Institute, Whitehead Institute, and the Massachusetts Institute of Technology. Tuschl is now at Rockefeller University.

The patent covers the use of siRNAs in inhibiting gene expression in mammalian cells. The license grants Sirna rights to the "undivided interest" of the Medical School in the Tuschl et al., IP for uses relating to human and veterinary therapeutic, prophylactic, diagnostic, and health care applications.

A Sirna spokeswoman told GenomeWeb News that the deal gives Sirna "exclusive access to UMass's position" on the intellectual property, except for a limited number of targets for which the company has non-exclusive rights to the technology.

Alnylam Holdings, one of Sirna's competitors in the RNAi sector, previously licensed the remaining portion of the intellectual property owned by Max-Planck, Whitehead, and MIT.

Under the terms of the license agreement, the UMass Medical School will receive licensing fees in cash and common stock from Sirna, and may receive additional cash and common stock following the achievement of certain milestones. The Medical School may also receive royalties on commercial product sales covered by the licensed patents.

Sirna said that it would share any revenues generated from the sublicensing of the patent to the Medical School.

Howard Robin, president and CEO of Sirna, said the company plans "to broadly offer sublicenses to this intellectual property."

Sirna said in August  that it plans to begin clinical trials of at least one siRNA drug candidate next year.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.